Longeveron is focusing on using its primary treatment, laromestrocel, to fight a rare pediatric heart birth defect that devastates families and continues to receive good FDA news regarding its treatment for Alzheimer's Disease, while also expanding its pipeline. The company announced its 2Q 2025 earnings results that showed good cost discipline and improving revenue as ongoing clinical trials pose potential inflection points for LGVN.
